Skip to Content
Merck
All Photos(1)

Documents

B7188

Sigma-Aldrich

Blonanserin

≥98% (HPLC)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H30FN3
CAS Number:
132810-10-7
Molecular Weight:
367.50
MDL number:
MFCD00893838
UNSPSC Code:
12352200
PubChem Substance ID:
329773292
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: ≥10 mg/mL

originator

Dainippon Sumitomo

storage temp.

room temp

SMILES string

CCN1CCN(CC1)c2cc(-c3ccc(F)cc3)c4CCCCCCc4n2

InChI

1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3

InChI key

XVGOZDAJGBALKS-UHFFFAOYSA-N

Biochem/physiol Actions

Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.

Features and Benefits

This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H413

Precautionary Statements

P273 - P301 + P312 + P330

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ming Peng et al.
Journal of chromatographic science, 50(8), 727-732 (2012-05-19)
Blonanserin is a novel atypical antipsychotic agent for the treatment of schizophrenia. Ethyl alcohol, isopropyl alcohol and toluene are utilized in the synthesis route of this bulk drug. A new validated gas chromatographic (GC) method for the simultaneous determination of
Koji Kato et al.
Psychiatry and clinical neurosciences, 65(4), 389-391 (2011-05-17)
The purpose of the present study was to provide preliminary data on the usefulness and safety of blonanserin for patients with delirium in the intensive care unit (ICU). The charts of 32 consecutive patients with delirium in the ICU were
Tomomi Tenjin et al.
Human psychopharmacology, 27(1), 90-100 (2012-01-27)
The purpose of this study was to evaluate the effects of blonanserin, a novel antipsychotic, on cognitive function in first-episode schizophrenia. Twenty-four antipsychotic-naïve patients with first-episode schizophrenia participated in the study. Blonanserin was given in an open-label design for 8 weeks.
Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Yutaro Suzuki et al.
Psychiatry and clinical neurosciences, 66(6), 534-535 (2012-10-17)
Three cases of schizophrenia showing improvement after switching to blonanserin.
Naohiro Kurotaki et al.
Psychiatry and clinical neurosciences, 65(4), 396-397 (2011-06-21)
View All Related Papers

Articles

Serotonin Receptors

We offer many products related to serotonin receptors for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service